Immune system alterations by aldosterone during hypertension: From clinical observations to genomic and non-genomic mechanisms leading to vascular damage

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 1035-1046

  Munoz Durango N ^a   Barake, M F ^a   Letelier, N A ^a   Campino, C ^a   Fardella, C E ^a   Kalergis, A M ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSERM   (France)

Author keywords

Aldosterone; GPR30; Hypertension; Inflammation; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CANRENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR 30; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1; VASCULOTROPIN A;

ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

EID: 84881337647     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313060015     Document Type: Article

References (110)

1. Muller-Fielitz H, Lau M, Johren O, Stellmacher F, Schwaninger M, Raasch W. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol 2012; 166: 2417-2429.
2. Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010; 6: 83-93.
3. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
4. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012; 81: 955-968.
5. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 2006; 147: 5564-5567.
6. Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL. Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 1993; 13: 2031-2040.
7. Tallec LP, Kirsh O, Lecomte MC, et al. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 2003; 17: 2529-2542.
8. Obradovic D, Tirard M, Nemethy Z, Hirsch O, Gronemeyer H, Almeida OF. DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells--toward a basis for the opposite actions elicited by two nuclear receptors? Mol Pharmacol 2004; 65: 761-769.
9. Yang J, Young MJ. The mineralocorticoid receptor and its coregulators. J Mol Endocrinol 2009; 43: 53-64.
10. Funder JW. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 2004; 217: 263-269.
11. Fiebeler A, Muller DN, Shagdarsuren E, Luft FC. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr Opin Nephrol Hypertens 2007; 16: 134-142.
12. Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15: 1993-2001.
13. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005; 10: 15-22.
14. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005; 70: 347-351.
15. Kitagawa H, Yanagisawa J, Fuse H, et al. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 2002; 22: 3698-3706.
16. Nagase M, Ayuzawa N, Kawarazaki W, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 2012; 59: 500-506.
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
18. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050.
19. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
20. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
21. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27.
22. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
23. Martins LC, Figueiredo VN, Quinaglia T, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011; 25: 532-538.
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
25. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
26. Catena C, Colussi G, Brosolo G, Iogna-Prat L, Sechi LA. Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. Am J Cardiovasc Dis 2012; 2: 50-57.
27. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645.
28. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009: CD007004.
29. Martinez-Aguayo A, Aglony M, Campino C, et al. Aldosterone, plasma renin activity, and aldosterone/rennin ratio in a normotensive healthy pediatric population. Hypertension 2010; 56: 391-396.
30. Loureiro C, Campino C, Martinez-Aguayo A, et al. Positive association between aldosterone-renin ratio and carotid intima-media thickness in hypertensive children. Clin Endocrinol (Oxf) 2013; 78: 352-357.
31. Luther JM, Gainer JV, Murphey LJ, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48: 1050-1957.
32. Benetos A, Gardner JP, Kimura M, et al. Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci 2005; 60: 1593-1596.
33. Kurata M, Okura T, Irita J, et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 358-363.
34. Irita J, Okura T, Manabe S, et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006; 19: 293-297.
35. Carvajal CA, Herrada AA, Castillo CR, et al. Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J Endocrinol Invest 2009; 32: 759-765.
36. Brattberg G, Bolund C, Brattgard B, et al. No to euthanasia. Yes to palliative care. Lakartidningen 1993; 90: 821-822.
37. Stehr CB, Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010; 28: 2120-2126.
38. Kotlyar E, Vita JA, Winter MR, et al. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 2006; 12: 122-127.
39. Krysiak R, Okopien B. The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma. Hypertens Res 2012; 35: 123-125.
40. Walczak C, Gaignier F, Gilet A, Zou F, Thornton SN, Ropars A. Aldosterone increases VEGF-A production in human neutrophils through PI3K, ERK1/2 and p38 pathways. Biochim Biophys Acta 2011; 1813: 2125-2132.
41. Calo LA, Zaghetto F, Pagnin E, et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 2004; 89: 1973-1976.
42. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643-650.
43. Sekizawa N, Yoshimoto T, Hayakawa E, Suzuki N, Sugiyama T, Hirata Y. Transcriptome analysis of aldosterone-regulated genes in human vascular endothelial cell lines stably expressing mineralocorticoid receptor. Mol Cell Endocrinol 2011; 341: 78-88.
44. Latouche C, Sainte-Marie Y, Steenman M, et al. Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 2010; 151: 4467-4476.
45. Queisser N, Schupp N. Aldosterone, oxidative stress, and NF-kappaB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med 2012; 53: 314-327.
46. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2008; 295: H281-H288.
47. Schupp N, Kolkhof P, Queisser N, et al. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 2011; 25: 968-978.
48. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294: H1067-H1074.
49. Zhang A, Jia Z, Wang N, Tidwell TJ, Yang T. Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int 2011; 80: 51-60.
50. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-507.
51. Martin-Ventura JL, Madrigal-Matute J, Martinez-Pinna R, et al. Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thromb Haemost 2012; 108: 435-442.
52. Saha P, Modarai B, Humphries J, et al. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol 2009; 9: 109-118.
53. Chiba T, Umegaki K. Pivotal roles of monocytes/macrophages in stroke. Mediators Inflamm 2013; 2013: 759103.
54. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-2460.
55. Schiffrin EL. T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 2010; 19: 181-186.
56. Ramesh C, Bryant B, Nayak T, et al. Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates. J Am Chem Soc 2006; 128: 14476-14476.
57. Bu DX, Lichtman AH. T cells and blood vessels: costimulation turns up the pressure. Circulation 2010; 122: 2495-2498.
58. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
59. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106-2113.
60. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124: 1370-1381.
61. Liu Y, Liu T, McCarron RM, et al. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996; 270: H2125-H2131.
62. Capers Q 4th, Alexander RW, Lou P, et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397-1402.
63. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.
64. Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004; 94: 1203-1210.
65. Dorffel Y, Latsch C, Stuhlmuller B, et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-7.
66. Zhao Z, Ni Y, Chen J, et al. Increased migration of monocytes in essential hypertension is associated with increased transient receptor potential channel canonical type 3 channels. PLoS One 2012; 7: e32628.
67. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens 2011; 29: 1684-1692.
68. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120: 3350-3364.
69. Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010; 184: 191-202.
70. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119: 1424-1432.
71. Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011; 106: 125-134.
72. de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010; 220: 499-508.
73. Jafarzadeh A, Esmaeeli-Nadimi A, Nough H, Nemati M, Rezayati MT. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease. Anadolu Kardiyol Derg 2009; 9: 75-83.
74. Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 2013; 34: 570-577.
75. Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011; 57: 469-476.
76. Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012; 59: 324-330.
77. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
78. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Tolllike receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444-454.
79. Kunes J, Poirier M, Tremblay J, Hamet P. Expression of hsp70 gene in lymphocytes from normotensive and hypertensive humans. Acta Physiol Scand 1992; 146: 307-311.
80. Jastrzebski M, Czarnecka D, Rajzer M, Kawecka-Jaszcz K. Increased levels of inflammatory markers in hypertensives with target organ damage. Kardiol Pol 2006; 64: 802-809; discussion 10-1.
81. Moen RJ, La Voi KP, Zhang M, Blake MJ. Clonidine-Induced Heat-Shock Protein Expression in Rat Aorta. J Cardiovasc Pharmacol Ther 1998; 3: 171-184.
82. Coppo M, Bandinelli M, Berni A, et al. Ang II Upregulation of the T-lymphocyte renin-angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens 2011; 24: 716-723.
83. Bomfim GF, Szasz T, Carvalho MH, Webb, RC. The Toll way to hypertension: role of the innate immune response. Endocrinol Metabol Syndrome 2011; S8: 002.
84. Gomez-Sanchez EP. Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends Endocrinol Metab 2011; 22: 179-187.
85. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57: 442-451.
86. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
87. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008; 70: 165-190.
88. Hasbi A, O'Dowd BF, George SR. A G protein-coupled receptor for estrogen: the end of the search? Mol Interv 2005; 5: 158-161.
89. O'Dowd BF, Nguyen T, Marchese A, et al. Discovery of three novel G-protein-coupled receptor genes. Genomics 1998; 47: 310-313.
90. Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol 2009; 297: C1178-C1187.
91. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-888.
92. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557-560.
93. Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol 2009; 296: F1323-F1333.
94. Batenburg WW, Jansen PM, van den Bogaerdt AJ, Danser AH. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc Res 2012; 94: 136-143.
95. Yuan Y, Zhang A, Huang S, Ding G, Chen R. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Am J Physiol Renal Physiol 2011; 300: F393-F402.
96. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005; 46: 701-706.
97. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47: 650-655.
98. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004; 44: 340-345.
99. Montezano AC, Callera GE, Yogi A, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-1518.
100. Min LJ, Mogi M, Iwanami J, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76: 506-516.
101. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32: 266-273.
102. Molnar GA, Lindschau C, Dubrovska G, et al. Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 2008; 51: 1372-1378.
103. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 153-162.
104. Lindsey SH, Chappell MC. Evidence that the G protein-coupled membrane receptor GPR30 contributes to the cardiovascular actions of estrogen. Gend Med 2011; 8: 343-354.
105. Lindsey SH, Yamaleyeva LM, Brosnihan KB, Gallagher PE, Chappell MC. Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2. Lewis rat. Hypertension 2011; 58: 665-671.
106. Chen YF. Sexual dimorphism of hypertension. Curr Opin Nephrol Hypertens 1996; 5: 181-185.
107. Fourrier F, Jallot A, Leclerc L, et al. Sex steroid hormones in circulatory shock, sepsis syndrome, and septic shock. Circ Shock 1994; 43: 171-178.
108. Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008; 78: 432-437.
109. Rettew JA, McCall SH, Marriott I. GPR30/GPER-1 mediates rapid decreases in TLR4 expression on murine macrophages. Mol Cell Endocrinol 2010; 328: 87-92.
110. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 2007; 292: E1790-E1800.